Our Work
›
Our Pipeline
BPL
-
003

Our novel synthetic intranasal formulation of 5-MeO-DMT benzoate

Treatment with BPL-003 comprises administration of BPL-003 in a clinical setting, with pre-dose preparation, in-dose safety monitoring and post-dose follow-up provided by healthcare professionals to support patients and ensure the safe use of the compound. 

The BPL-003 treatment has been designed to overcome some of the challenges of first-generation psychedelics and existing mental health treatments and produce rapid, robust and lasting treatment effects with a short time in clinic of 2 hours. 

Rapid, robust and lasting response from a single dose

Findings from an open-label Phase IIa study investigating 10mg of BPL-003 in patients with Treatment Resistant Depression (depression that failed to respond to two or more prior treatments) who were not taking concomitant antidepressants found that:

A single administration of BPL-003 demonstrated a rapid antidepressant effect, with 55% of patients having a 50% or greater improvement in depression symptoms the day after dosing (day 2).
A robust and lasting antidepressant effect was shown, with 55% of patients meeting the criteria for remission from symptoms of depression at day 29 and 45% in remission at day 85. 
BPL-003 required a short time in clinic, with patients deemed dischargeable within an average time of less than 2 hours. This underlies the potential to deliver a scalable treatment model that, if approved, could fit within the existing interventional psychiatry treatment paradigm.
Read press release
More about
Ongoing Clinical Trials of BPL-003
Depression
Substance Use Disorders